Description of Medical ServiceThe RAS mutation test is a combination of genetic tests, conducted on a biopsy sample, to tell whether a tumour carries a RAS mutation(s). KRAS and NRAS are highly related members of the RAS oncogene family which have an important role in the development and continued growth of colorectal cancer. The KRAS gene is found to be mutated, or changed, in about 40% of people with colorectal cancer. The NRAS gene is found to be mutated in an additional 10-15% of patients. The other ~50% of people have a non-mutated (sometimes called “wild type”) RAS genes.
Description of Medical ConditionWidespread colorectal cancer is treated with chemotherapy and patients may receive several sequential courses of different types of chemotherapy as the disease progresses. For patients with widespread disease the prognosis is poor with only 10% of patients still alive 5 years after diagnosis.
Reason for ApplicationNew MBS item
Medical Service TypeInvestigative
Previous Application NumberNot Applicable
Public Summary DocumentPublic Summary Document (PDF 181 KB)
Public Summary Document (Word 158 KB)
Predicted versus ActualPublic Summary Document - July 2018 (PDF 1252 KB)
Public Summary Document - July 2018 (Word 133 KB)
Meetings for this Application
ESC12 and 13 June 2014
MSAC3 October 2014
27 July 2018